NCT05809817

Brief Summary

The goal of this study is to evaluate the cost-effectiveness of the current proposal and different decision-making scenarios of periodontal care coverage increases for patients with T2DM in Chile. The main objective of the clinical section of this study (effectiveness) aims to determine the effectiveness of periodontal care in patients with T2DM under follow-up in the Cardiovascular Health Program (Programa de Salud Cardiovascular, PSCV) of the in the CEMO Villa Sur of Pedro Aguirre Cerda and the CESFAM Antonio Varas of Puerto Montt. A highly matched control group is proposed using Propensity Score Matching of PSCV patients with T2DM who have not received periodontal care. This would allow a better comparison of the individuals who will actually be treated against a counterfactual against of those with similar characteristics who did not receive periodontal intervention during the follow-up period of this first stage.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
135

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2023

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2023

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

March 10, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 12, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

March 7, 2024

Status Verified

March 1, 2023

Enrollment Period

1.2 years

First QC Date

March 10, 2023

Last Update Submit

March 6, 2024

Conditions

Keywords

PeriodonticsPeriodontal MedicineType 2 Diabetes MellitusNon-surgical Periodontal TherapyDiabetic complicationCost-Effectiveness Analysis

Outcome Measures

Primary Outcomes (1)

  • Metabolic control

    Mean change from baseline HbA1c at 3 months after periodontal treatment

    Baseline and 3 months after periodontal treatment

Study Arms (2)

Intervention (Periodontal treatment)

Patients with T2DM under follow-up in the PSCV will receive the usual periodontal therapy performed at the CEMO Villa Sur in the commune of Pedro Aguirre Cerda and at the CESFAM Puerto Varas in the context of PSCV. The care protocols and national evidence establish that the standard treatment of periodontitis consists of 4 or more sessions of scaling and root planing per sextant, depending on the severity of the disease.

Procedure: Periodontal treatment

Control (Matched, non-active intervention)

Patients with T2DM under follow-up in the PSCV, with non-active control (withouth periodontal treatment) that will be matched in a ratio of 1:1 through Propensity Score Matching according to baseline HbA1c levels and demographic baseline data (age, sex).

Interventions

Scaling and root planing

Intervention (Periodontal treatment)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with T2DM under follow-up in the PSCV

You may qualify if:

  • Intervention: Patients with T2DM under follow-up in the PSCV who present records of HbA1c levels for the last three months prior to care and who receive complete periodontal treatment at the CEMO Villa Sur in the commune of Pedro Aguirre Cerda and at the CESFAM Puerto Varas in Puerto Montt under the PSCV will be selected.
  • Control: A control cohort of patients with T2DM under follow-up in the PSCV will be determined, matching 1:1 through Propensity Score Matching according to baseline HbA1c levels and demographic baseline data (age and sex).

You may not qualify if:

  • Patients with a history of periodontal treatment.
  • Pregnant or breastfeeding.
  • Time spent in PSCV\<1year.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CESFAM Puerto VARAS

Puerto Varas, De Los Rios, Chile

Location

CEMO Villa Sur

Santiago, 8480437, Chile

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2PeriodontitisDiabetes Complications

Interventions

Periodontal Index

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesPeriodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Dental Health SurveysHealth SurveysSurveys and QuestionnairesData CollectionEpidemiologic MethodsInvestigative TechniquesDentistryPeriodonticsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthPublic Health Dentistry

Study Officials

  • Mauricio Baeza, DDS,MSc,PhD

    Department of Conservative Dentistry, Faculty of Dentistry, University of Chile

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 10, 2023

First Posted

April 12, 2023

Study Start

March 1, 2023

Primary Completion

May 1, 2024

Study Completion

December 1, 2024

Last Updated

March 7, 2024

Record last verified: 2023-03

Locations